148 related articles for article (PubMed ID: 2952262)
1. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of trimetrexate in combination with cisplatin.
Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
[TBL] [Abstract][Full Text] [Related]
3. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
[TBL] [Abstract][Full Text] [Related]
4. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
5. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Lin JT; Cashmore AR; Baker M; Dreyer RN; Ernstoff M; Marsh JC; Bertino JR; Whitfield LR; Delap R; Grillo-Lopez A
Cancer Res; 1987 Jan; 47(2):609-16. PubMed ID: 2947679
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.
Balis FM; Lester CM; Poplack DG
Cancer Res; 1986 Jan; 46(1):169-74. PubMed ID: 2933145
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; GrĂ¼ndel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Grochow LB; Noe DA; Dole GB; Rowinsky EK; Ettinger DS; Graham ML; McGuire WP; Donehower RC
J Natl Cancer Inst; 1989 Jan; 81(2):124-30. PubMed ID: 2909752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]